A class action filed in New Jersey alleges ADMA Biologics inflated its 2025 revenue through channel stuffing and an undisclosed related-party distributor tied to its own vice chairman. In two trading days, the stock lost twenty-nine percent.
A short seller said ADMA's 20% growth was really a 3% decline hidden in distributor warehouses. The stock fell 29% in two days. Now the lawsuits are stacking up.
By Mark Tell · Jun 11
Daily at 6AM Eastern
See the pitch they're running today.
Financial crime intelligence. The patterns, the tells, the playbook. Daily at 6AM before anyone asks you for money.
By subscribing you agree to receive the daily MarkTell digest. Free forever. Unsubscribe anytime.
The MarkTell Daily
Tomorrow's pitch, decoded today.
Financial crime intelligence. The patterns, the tells, the playbook. Daily at 6AM before anyone asks you for money.
By subscribing you agree to receive the daily MarkTell digest. Free forever. Unsubscribe anytime.
